Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has received diverse analyst ratings, with a majority being bullish. The average 12-month price target has increased by 18.57% to $21.96. The company shows strong revenue growth but faces challenges in debt management and returns on equity and assets.
October 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics has received predominantly bullish analyst ratings, with an increase in the average 12-month price target to $21.96. The company shows strong revenue growth but faces challenges in debt management and returns on equity and assets.
The majority of analysts have given bullish ratings to Travere Therapeutics, indicating positive sentiment. The increase in the average price target suggests expectations of stock price appreciation. However, financial metrics like ROE and debt management indicate potential risks, which may temper the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100